## Appendix 1. Acknowledgments

The authors would like to express our appreciation for all the individuals and institutions who have contributed to this study.

The following NRG Oncology/Gynecologic Oncology Group member institutions participated in the primary treatment studies: Odette Cancer Centre-Sunnybrook Health Sciences Centre, University of Oklahoma Health Sciences Center – Anschutz Cancer Pavilion, Women's Cancer Center of Nevada, UCSF-Mount Zion, University of Colorado Cancer Center - Anschutz Cancer Pavilion, University of Texas Southwestern Medical Center, The Hospital of Central Connecticut, Northwestern University, Memorial University Medical Center, Abington Memorial Hospital, State University of New York Downstate Medical Center, Olive View-University of California Los Angeles Medical Center, Stanford University Hospitals and Clinics, University of New Mexico, Cleveland Clinic Foundation and Carilion Clinic Gynecological Oncology.

Osborne RJ, Filiaci V, Schink JC, Mannel RS, Behbakht K, Hoffman JS, et al. Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia. Obstet Gynecol 2016; 128.

The authors provided this information as a supplement to their article.